Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.62M | $46.80M | $140.73M | $235.31M | $176.32M | $256.58M | $212.96M | $125.67M |
| Cost of Revenue | $15.56M | $3.96M | $20.28M | $449.19M | $8.87M | $1.15M | $235.84M | $196.52M |
| Gross Profit | $14.06M | $42.84M | $120.45M | $-213.88M | $167.45M | $255.43M | $-22.88M | $-70.85M |
| Gross Margin | 47.47% | 91.53% | 85.59% | -90.89% | 94.97% | 99.55% | -10.74% | -56.38% |
| Operating Expenses | $164.48M | $365.56M | $421.48M | $74.65M | $359.33M | $344.74M | $63.81M | $51.76M |
| Operating Income | $-150.42M | $-322.72M | $-301.02M | $-288.53M | $-191.88M | $-89.31M | $-86.69M | $-122.61M |
| Operating Margin | -507.80% | -689.53% | -213.90% | -122.62% | -108.83% | -34.81% | -40.71% | -97.57% |
| Net Income | $-47.58M | $-284.23M | $-293.65M | $-290.02M | $-189.29M | $-76.97M | $-86.42M | $-126.20M |
| Net Margin | -160.63% | -607.29% | -208.66% | -123.25% | -107.36% | -30.00% | -40.58% | -100.43% |
| EPS (Basic) | $-0.48 | $-2.92 | $-3.15 | $-3.15 | $-2.11 | $-0.89 | $-1.03 | $-1.73 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |